SN 35210

In this article, we are going to delve into the fascinating world of SN 35210 and explore all its facets. SN 35210 is a topic that has captured the attention of many people over the years, and its importance and impact on our lives cannot be underestimated. From its origin to its current evolution, SN 35210 has left an indelible mark on our society and culture. Throughout this article, we will examine its influence in different areas, as well as its relevance in the contemporary world. Get ready to discover everything SN 35210 has to offer and enter a world full of knowledge and wisdom.

SN 35210
Clinical data
ATC code
  • none
Legal status
Legal status
Identifiers
  • Methyl 4-{amino}pentanoate
CAS Number
PubChem CID
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H24ClNO3
Molar mass337.84 g·mol−1
3D model (JSmol)
  • Clc1ccccc1C2(NCCCCC(=O)OC)CCCCC2=O
  • InChI=1S/C18H24ClNO3/c1-23-17(22)11-5-7-13-20-18(12-6-4-10-16(18)21)14-8-2-3-9-15(14)19/h2-3,8-9,20H,4-7,10-13H2,1H3
  • Key:QFFBIIVCZDWTKZ-UHFFFAOYSA-N

SN 35210 is an arylcyclohexylamine dissociative anesthetic drug. It was derived from ketamine with the intention of producing a shorter acting agent more suitable to be used as a stand-alone drug, whereas ketamine itself generally has to be used in combination with other drugs such as midazolam to minimise the occurrence of emergence reactions due to its hallucinogenic side effects. In common with other short-acting anaesthetic drugs such as remifentanil and remimazolam, SN 35210 has had the chemical structure modified to incorporate a methyl ester group which is rapidly metabolised to a carboxylic acid, producing an inactive compound and thus rapidly terminating the effects of the drug. It was selected for development from a series of structurally related alkyl esters due to having the shortest duration of action and the most similar pharmacological profile to ketamine itself.[1][2][3][4][5]

References

  1. ^ Jose J, Gamage SA, Harvey MG, Voss LJ, Sleigh JW, Denny WA (September 2013). "Structure-activity relationships for ketamine esters as short-acting anaesthetics". Bioorganic & Medicinal Chemistry. 21 (17): 5098–106. doi:10.1016/j.bmc.2013.06.047. PMID 23876339.
  2. ^ Harvey M, Sleigh J, Voss L, Jose J, Gamage S, Pruijn F, et al. (October 2015). "Development of Rapidly Metabolized and Ultra-Short-Acting Ketamine Analogs". Anesthesia and Analgesia. 121 (4): 925–33. doi:10.1213/ANE.0000000000000719. PMID 25822925. S2CID 23288200.
  3. ^ Harvey M, Sleigh J, Voss L, Pruijn F, Jose J, Gamage S, Denny W (2015). "Determination of the Hypnotic Potency in Rats of the Novel Ketamine Ester Analogue SN 35210". Pharmacology. 96 (5–6): 226–32. doi:10.1159/000439598. PMID 26352278. S2CID 36017002.
  4. ^ Jacobson GM, Voss LJ, Klockars A, Bird S, Dimitrov I, Denny WA, et al. (April 2019). "Transcriptional changes in response to ketamine ester-analogs SN 35210 and SN 35563 in the rat brain". BMC Genomics. 20 (1): 281. doi:10.1186/s12864-019-5649-6. PMC 6458767. PMID 30971208.
  5. ^ Harvey M, Sleigh J, Voss L, Bickerdike M, Dimitrov I, Denny W (December 2019). "KEA-1010, a ketamine ester analogue, retains analgesic and sedative potency but is devoid of Psychomimetic effects". BMC Pharmacology & Toxicology. 20 (1): 85. doi:10.1186/s40360-019-0374-y. PMC 6923863. PMID 31856925.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.